CALIDI BIOTHERAPEUTICS INC(CLDI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CLDI CALIDI BIOTHERAPEUTICS INC

未开盘 08-18 16:00:00 EDT

1.27

-0.09

-6.62%

盘后1.30

+0.03+2.36%

19:11 EDT

最高1.34	最低1.25	成交量13.57万
今开1.32	昨收1.36	日振幅6.62%
总市值328.19万	流通市值324.54万	总股本258.42万
成交额17.69万	换手率5.31%	流通股本255.54万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CLDI","market":"US","secType":"STK","nameCN":"CALIDI BIOTHERAPEUTICS INC","latestPrice":1.27,"timestamp":1787083200000,"preClose":1.36,"halted":0,"volume":135748,"hourTrading":{"tag":"盘后","latestPrice":1.3,"preClose":1.27,"latestTime":"19:11 EDT","volume":6151,"amount":8055.6728,"timestamp":1787094717986,"change":0.03,"changeRate":0.023622,"amplitude":0.062992},"delay":0,"changeRate":-0.06617647058823535,"floatShares":2555400,"shares":2584200,"eps":-33.337368,"marketStatus":"未开盘","change":-0.09,"latestTime":"08-18 16:00:00 EDT","open":1.32,"high":1.34,"low":1.25,"amount":176910.4859456,"amplitude":0.066176,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-33.337368,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787126400000},"marketStatusCode":0,"adr":0,"exchange":"AMEX","adjPreClose":1.36,"preHourTrading":{"tag":"盘前","latestPrice":1.3,"preClose":1.36,"latestTime":"09:28 EDT","volume":15247,"amount":20120.5876728,"timestamp":1787059735110,"change":-0.06,"changeRate":-0.044118,"amplitude":0.066176},"postHourTrading":{"tag":"盘后","latestPrice":1.3,"preClose":1.27,"latestTime":"19:11 EDT","volume":6151,"amount":8055.6728,"timestamp":1787094717986,"change":0.03,"changeRate":0.023622,"amplitude":0.062992},"volumeRatio":0.693015},"requestUrl":"/m/hq/s/CLDI","defaultTab":"news","newsList":[{"id":"1154283209","title":"Calidi宣布反向股票分割，预计将于2026年7月31日以1比16的调整后比例开始交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1154283209","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154283209?lang=zh_cn&edition=full","pubTime":"2026-07-21 04:32","pubTimestamp":1784579569,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc宣布将进行反向股票分割，预计公司股票将于2026年7月31日以1比16的调整后比例开始交易。此举旨在调整公司的股本结构。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154584198","title":"Calidi Biotherapeutics任命前基因泰克/罗氏与Celgene高管Corsee Sanders博士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1154584198","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154584198?lang=zh_cn&edition=full","pubTime":"2026-06-23 20:03","pubTimestamp":1782216238,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics宣布，任命在生物技术领域拥有丰富经验的前基因泰克/罗氏及Celgene公司高管Corsee Sanders博士加入其董事会。此项人事任命旨在强化公司的战略指导与治理能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI","LEGN","BK4585","BK4505","RARE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124481970","title":"Calidi Biotherapeutics获美国FDA对Cld-401的积极Pre-IND反馈，就当前开发策略达成一致，推进首次人体研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1124481970","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124481970?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:01","pubTimestamp":1781611291,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics公司宣布，其候选疗法Cld-401已获得美国食品药品监督管理局（FDA）积极的Pre-IND（研究性新药申请前）会议反馈。这一进展标志着监管机构与公司就Cld-401当前的整体开发策略达成共识，为推进该疗法进入首次人体临床研究扫清了关键路径。公司正基于此反馈，积极准备后续的IND申请工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178176076","title":"Calidi Biotherapeutics：目标年底前提交CLD-401监管申请，首个人体试验拟于2027年初启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1178176076","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178176076?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:00","pubTimestamp":1781611259,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics公司宣布，其目标是在今年年底前完成候选疗法CLD-401的监管申请提交。若进展顺利，公司计划于2027年初启动该疗法的首次人体临床试验。这一时间表标志着该公司在推进其新型生物治疗平台方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116899755","title":"Calidi Biotherapeutics与Transferai达成战略合作 运用智能代理AI优化Cld-401新药临床申请流程","url":"https://stock-news.laohu8.com/highlight/detail?id=1116899755","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116899755?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:01","pubTimestamp":1777464078,"startTime":"0","endTime":"0","summary":"生物技术公司Calidi Biotherapeutics近日宣布与人工智能企业Transferai建立战略合作伙伴关系。双方将重点运用智能代理人工智能技术，显著提升抗癌候选药物Cld-401的新药临床试验申请准备工作的效率。通过此次合作，Calidi计划借助Transferai先进的AI解决方案优化IND申报流程中的关键环节。Cld-401作为Calidi公司核心的肿瘤治疗候选药物，此次与AI技术企业的合作标志着其商业化进程进入新阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109014411","title":"Calidi Biotherapeutics 公布2025年第四季度及全年财务业绩与近期运营亮点","url":"https://stock-news.laohu8.com/highlight/detail?id=1109014411","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109014411?lang=zh_cn&edition=full","pubTime":"2026-03-28 04:26","pubTimestamp":1774643190,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics 发布了2025年第四季度及全年的财务业绩报告，并同步更新了公司近期的运营进展。公司在此期间持续推进其生物治疗技术的研发与应用，展现了在创新疗法领域的持续投入与阶段性成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131366728","title":"Calidi Biotherapeutics与Avance Clinical达成合作，旨在加速澳大利亚监管审批并推进Cld-401临床试验启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1131366728","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131366728?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:17","pubTimestamp":1774354633,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics（简称CLDI）宣布与Avance Clinical建立合作伙伴关系，双方将共同推进在澳大利亚的监管审批流程，并加速启动Cld-401的临床试验。这一合作有望为Calidi Biotherapeutics的临床开发计划提供重要支持，助力其加快创新疗法的落地进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122220268","title":"Calidi Biotherapeutics完成600万美元承销公开发行 承销商超额配售权获全额行使","url":"https://stock-news.laohu8.com/highlight/detail?id=1122220268","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122220268?lang=zh_cn&edition=full","pubTime":"2026-03-10 08:51","pubTimestamp":1773103909,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics（股票代码：CLDI）宣布已完成600万美元的承销公开发行。此次发行中，承销商全额行使了超额配售选择权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617456724","title":"Calidi Biotherapeutics, Inc.盘中异动 早盘股价大涨6.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617456724","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2617456724?lang=zh_cn&edition=full","pubTime":"2026-03-04 22:56","pubTimestamp":1772636164,"startTime":"0","endTime":"0","summary":"北京时间2026年03月04日22时56分，Calidi Biotherapeutics, Inc.股票出现波动，股价大幅拉升6.43%。Calidi Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。其相关个股中，Can Fite Biopharma Ltd、Scisparc Ltd.、Moolec Science Sa C/Wts 30/01/2028涨幅较大，Can Fite Biopharma Ltd、Klotho Neurosciences, Inc.、Onconetix, Inc.较为活跃，换手率分别为2160.20%、49.83%、34.07%，振幅较大的相关个股有Klotho Neurosciences, Inc.、Can Fite Biopharma Ltd、Klotho Neurosciences Inc C/Wts 21/06/2029 ，振幅分别为51.24%、41.60%、39.80%。Calidi Biotherapeutics, Inc.公司简介：Calidi Biotherapeutics Inc 是一家临床阶段的免疫肿瘤学公司，技术主要在武装免疫系统以对抗癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304225604a6a2a4ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304225604a6a2a4ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAA","BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614511580","title":"Calidi Biotherapeutics, Inc.盘中异动 股价大涨7.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614511580","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2614511580?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:34","pubTimestamp":1772030064,"startTime":"0","endTime":"0","summary":"北京时间2026年02月25日22时34分，Calidi Biotherapeutics, Inc.股票出现异动，股价大幅拉升7.84%。Calidi Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，Moolec Science Sa C/Wts 30/01/2028、Surrozen Inc C/Wts 01/08/2031 、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 涨幅较大，Quince Therapeutics, Inc.、Ensysce Biosciences, Inc.、Edesa Biotech, Inc.较为活跃，换手率分别为157.39%、20.78%、14.14%，振幅较大的相关个股有Larimar Therapeutics, Inc.、Onkure Therapeutics, Inc.、Moolec Science Sa C/Wts 30/01/2028，振幅分别为15.45%、11.37%、10.90%。Calidi Biotherapeutics, Inc.公司简介：Calidi Biotherapeutics Inc 是一家临床阶段的免疫肿瘤学公司，技术主要在武装免疫系统以对抗癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225223424a71e8e6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225223424a71e8e6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLDI","BK4139","AAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518227961","title":"Calidi Biotherapeutics, Inc.盘中异动 早盘大幅下挫5.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518227961","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518227961?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:00","pubTimestamp":1741615251,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时00分，Calidi Biotherapeutics, Inc.股票出现异动，股价快速跳水5.64%。Calidi Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Calidi Biotherapeutics, Inc.公司简介：Calidi Biotherapeutics Inc 是一家临床阶段的免疫肿瘤学公司，致力于开发和商业化新型、强效和高效的基于干细胞的平台，用于递送和增强用于治疗癌症的溶瘤病毒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022005198a2a4be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022005198a2a4be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517049910","title":"Calidi Biotherapeutics, Inc.盘中异动 早盘大幅上涨6.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517049910","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517049910?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:30","pubTimestamp":1741185035,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时30分，Calidi Biotherapeutics, Inc.股票出现波动，股价大幅拉升6.81%。Calidi Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Calidi Biotherapeutics, Inc.公司简介：Calidi Biotherapeutics Inc 是一家临床阶段的免疫肿瘤学公司，致力于开发和商业化新型、强效和高效的基于干细胞的平台，用于递送和增强用于治疗癌症的溶瘤病毒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223035963adbed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223035963adbed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516217658","title":"Calidi Biotherapeutics, Inc.盘中异动 股价大跌5.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516217658","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516217658?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:53","pubTimestamp":1741017224,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时53分，Calidi Biotherapeutics, Inc.股票出现异动，股价快速下挫5.63%。Calidi Biotherapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.38%。Calidi Biotherapeutics, Inc.公司简介：Calidi Biotherapeutics Inc 是一家临床阶段的免疫肿瘤学公司，致力于开发和商业化新型、强效和高效的基于干细胞的平台，用于递送和增强用于治疗癌症的溶瘤病毒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303235344abe64ecc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303235344abe64ecc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514861543","title":"Calidi Biotherapeutics, Inc.盘中异动 急速下挫6.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514861543","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514861543?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:59","pubTimestamp":1740668382,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时59分，Calidi Biotherapeutics, Inc.股票出现异动，股价快速跳水6.15%。Calidi Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.99%。Calidi Biotherapeutics, Inc.公司简介：Calidi Biotherapeutics Inc 是一家临床阶段的免疫肿瘤学公司，致力于开发和商业化新型、强效和高效的基于干细胞的平台，用于递送和增强用于治疗癌症的溶瘤病毒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272259429632b718&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272259429632b718&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514856304","title":"Calidi Biotherapeutics, Inc.盘中异动 早盘急速上涨5.72%报0.900美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856304","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514856304?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:35","pubTimestamp":1740580505,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时35分，Calidi Biotherapeutics, Inc.股票出现异动，股价快速拉升5.72%。Calidi Biotherapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.01%。Calidi Biotherapeutics, Inc.公司简介：Calidi Biotherapeutics Inc 是一家临床阶段的免疫肿瘤学公司，致力于开发和商业化新型、强效和高效的基于干细胞的平台，用于递送和增强用于治疗癌症的溶瘤病毒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223505abddedd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223505abddedd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514905930","title":"Calidi Biotherapeutics, Inc.盘中异动 早盘股价大跌5.26%报0.920美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514905930","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514905930?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:39","pubTimestamp":1740494381,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时39分，Calidi Biotherapeutics, Inc.股票出现波动，股价急速下跌5.26%。Calidi Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Calidi Biotherapeutics, Inc.公司简介：Calidi Biotherapeutics Inc 是一家临床阶段的免疫肿瘤学公司，致力于开发和商业化新型、强效和高效的基于干细胞的平台，用于递送和增强用于治疗癌症的溶瘤病毒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022522394198924e9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022522394198924e9b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513272240","title":"Calidi Biotherapeutics, Inc.盘中异动 股价大涨5.71%报1.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513272240","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513272240?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:34","pubTimestamp":1740407642,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时34分，Calidi Biotherapeutics, Inc.股票出现波动，股价急速拉升5.71%。Calidi Biotherapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.11%。Calidi Biotherapeutics, Inc.公司简介：Calidi Biotherapeutics Inc 是一家临床阶段的免疫肿瘤学公司，致力于开发和商业化新型、强效和高效的基于干细胞的平台，用于递送和增强用于治疗癌症的溶瘤病毒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223402a2521502&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223402a2521502&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513829734","title":"Calidi Biotherapeutics, Inc.盘中异动 急速下跌5.43%报1.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513829734","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513829734?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:10","pubTimestamp":1740154228,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日00时10分，Calidi Biotherapeutics, Inc.股票出现波动，股价大幅下挫5.43%。Calidi Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。Calidi Biotherapeutics, Inc.公司简介：Calidi Biotherapeutics Inc 是一家临床阶段的免疫肿瘤学公司，致力于开发和商业化新型、强效和高效的基于干细胞的平台，用于递送和增强用于治疗癌症的溶瘤病毒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222001028988df3ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222001028988df3ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512198030","title":"Calidi Biotherapeutics, Inc.盘中异动 急速下跌5.51%报1.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512198030","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512198030?lang=zh_cn&edition=full","pubTime":"2025-02-19 01:47","pubTimestamp":1739900871,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日01时47分，Calidi Biotherapeutics, Inc.股票出现异动，股价急速下跌5.51%。Calidi Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.64%。Calidi Biotherapeutics, Inc.公司简介：Calidi Biotherapeutics Inc 是一家临床阶段的免疫肿瘤学公司，致力于开发和商业化新型、强效和高效的基于干细胞的平台，用于递送和增强用于治疗癌症的溶瘤病毒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190147519627b79d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190147519627b79d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511525122","title":"Calidi Biotherapeutics, Inc.盘中异动 股价大跌5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511525122","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511525122?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:36","pubTimestamp":1739457369,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时36分，Calidi Biotherapeutics, Inc.股票出现波动，股价急速下跌5.33%。Calidi Biotherapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。Calidi Biotherapeutics, Inc.公司简介：Calidi Biotherapeutics Inc 是一家临床阶段的免疫肿瘤学公司，致力于开发和商业化新型、强效和高效的基于干细胞的平台，用于递送和增强用于治疗癌症的溶瘤病毒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502132236099621bcf6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502132236099621bcf6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.calidibio.com","stockEarnings":[{"period":"1week","weight":-0.2256},{"period":"1month","weight":-0.3324},{"period":"3month","weight":-0.5312},{"period":"6month","weight":-0.8915},{"period":"1year","weight":-0.9806},{"period":"ytd","weight":-0.9322}],"compareEarnings":[{"period":"1week","weight":-0.004},{"period":"1month","weight":0.0325},{"period":"3month","weight":0.0353},{"period":"6month","weight":0.1212},{"period":"1year","weight":0.193},{"period":"ytd","weight":0.1254}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Calidi Biotherapeutics, Inc.于2021年3月24日在特拉华州注册成立。该公司是一家公开交易的生物技术公司，率先利用其RedTail平台开发靶向疗法，该平台是一种工程化包膜溶瘤病毒，设计用于系统递送至转移部位。其主要候选药物CLD-401将IL-15超激动剂递送至肿瘤微环境，预计于2026年底提交新药临床试验申请。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.185839},{"month":2,"riseRate":0.6,"avgChangeRate":-0.062337},{"month":3,"riseRate":0.4,"avgChangeRate":-0.220856},{"month":4,"riseRate":0.2,"avgChangeRate":-0.161642},{"month":5,"riseRate":0.2,"avgChangeRate":-0.101283},{"month":6,"riseRate":0.6,"avgChangeRate":-0.072029},{"month":7,"riseRate":0.6,"avgChangeRate":0.19684},{"month":8,"riseRate":0.2,"avgChangeRate":-0.27858},{"month":9,"riseRate":0,"avgChangeRate":-0.182897},{"month":10,"riseRate":0.75,"avgChangeRate":-0.07151},{"month":11,"riseRate":0.5,"avgChangeRate":0.188661},{"month":12,"riseRate":0.2,"avgChangeRate":-0.191351}],"exchange":"AMEX","name":"CALIDI BIOTHERAPEUTICS INC","nameEN":"CALIDI BIOTHERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CALIDI BIOTHERAPEUTICS INC(CLDI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供CALIDI BIOTHERAPEUTICS INC(CLDI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"CALIDI BIOTHERAPEUTICS INC,CLDI,CALIDI BIOTHERAPEUTICS INC股票,CALIDI BIOTHERAPEUTICS INC股票老虎,CALIDI BIOTHERAPEUTICS INC股票老虎国际,CALIDI BIOTHERAPEUTICS INC行情,CALIDI BIOTHERAPEUTICS INC股票行情,CALIDI BIOTHERAPEUTICS INC股价,CALIDI BIOTHERAPEUTICS INC股市,CALIDI BIOTHERAPEUTICS INC股票价格,CALIDI BIOTHERAPEUTICS INC股票交易,CALIDI BIOTHERAPEUTICS INC股票购买,CALIDI BIOTHERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CALIDI BIOTHERAPEUTICS INC(CLDI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供CALIDI BIOTHERAPEUTICS INC(CLDI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}